All In Biotech

Drug Trial Radar · NCT03266653

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jul 7, 2020

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
New York Medical CollegeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Children's Hospital of Philadelphia; Medical College of Wisconsin; Nationwide Children's Hospital; Indiana University; Washington University School of Medicine; University of California, Los Angeles; University of California, San Francisco
First posted
Aug 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

Conditions

  • Epstein-Barr Virus Infections
  • Primary Immune Deficiency Disorder

Interventions

  • cytotoxic t-lymphocytesDrug

    EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Patients will be followed for 12 weeks after each infusion
  2. Incidence of Response to Treatment [Efficacy]Time frame: Patients will be followed for 12 weeks after each infusion

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hosptial Los Angeles

    Los Angeles, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Johns Hopkins

    Baltimore, Maryland · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • New York Medical College

    Valhalla, New York · Recruiting

  • Nationwide Children's Hosptial

    Columbus, Ohio · Recruiting

  • Children's Hospital of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Medical College of Wisconsin/Children's Hospital of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.